Nexentis Technologies Inc
NASDAQ:NXTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nexentis Technologies Inc
Research & Development
Nexentis Technologies Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nexentis Technologies Inc
NASDAQ:NXTS
|
Research & Development
-$199.5k
|
CAGR 3-Years
32%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
I
|
Israel Corporation Ltd
TASE:ILCO
|
Research & Development
-$70m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
ICL Group Ltd
TASE:ICL
|
Research & Development
-$70m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
Nexentis Technologies Inc
Glance View
N2OFF, Inc. is a cleantech company mainly engaged in European Union (EU) based solar assets using the Ready to Build (RTB) business model. The Company is an investor in four solar projects in three different EU countries. It collaborates with Solterra Renewable Energy Ltd., an Israeli corporation and a wholly owned subsidiary of Solterra Energy Ltd., an Israeli corporation, which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (PV) projects. The Company also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. The Company’s solutions are focused on improving the food safety and shelf life of fresh produce. The Company, through its subsidiary, MitoCareX Bio Ltd., is focused on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family.
See Also
What is Nexentis Technologies Inc's Research & Development?
Research & Development
-199.5k
USD
Based on the financial report for Sep 30, 2025, Nexentis Technologies Inc's Research & Development amounts to -199.5k USD.
What is Nexentis Technologies Inc's Research & Development growth rate?
Research & Development CAGR 5Y
19%
Over the last year, the Research & Development growth was 44%. The average annual Research & Development growth rates for Nexentis Technologies Inc have been 32% over the past three years , 19% over the past five years .
